Acute myeloid leukemia
Conditions
Interventions
Treatment group Control group:in vitro culture
Treatment group Control group:cytarabine
Treatment group Control group:Adriamycin
Treatment group Control group:Daunorubicin
Sponsors
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
Eligibility
Sex/Gender
All
Age
3 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Diagnosed of having an Acute Myeloid Leukemia; 2. No limit in gender and the patients aged 3 to 80 years; 3. Signed a patient authorization form to use and disclose personal health information (or informed consent; participants under 18 years or thoese loss language ability can be signed by their guardians).
Exclusion criteria
Exclusion criteria: 1. Diagnosed of having an Chronic Myeloid Leukemia; 2. Participates in a concurrent interventional clinical trial (phase 1, 2 or 3 or a Compassionate Use or Early Access Program).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Survival and proliferation in vitro;IL8 expression level;Efflux rate of chemotherapeutic agents;apoptosis rate;Expression levels of cell cycle and apoptosis related proteins;Adipogenic and osteogenic differentiation;Expression profile of IL8 related genes; | — |
Countries
China
Contacts
Public ContactTianxiang Pang
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
Outcome results
None listed